<DOC>
	<DOCNO>NCT01198756</DOCNO>
	<brief_summary>This study design test immunogenicity safety investigational influenza vaccine , child compare two influenza vaccine .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity GSK Biologicals ' Seasonal Influenza Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) legally acceptable representative ( ) comply requirement protocol . A male female child age 6 month 17 year inclusive time first vaccination ; child eligible regardless history administration influenza vaccine previous season . Written inform consent obtain subject/from parent ( ) /legally acceptable representative ( ) subject . Written inform assent obtain subject if/as require local regulation . Subjects stable health determine investigator 's clinical examination assessment subject ' medical history . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject Has practice adequate contraception 30 day prior vaccination , Has negative pregnancy urine test day vaccination , Has agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period.Prior receipt seasonal pandemic influenza vaccine within 6 month precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immune modify drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . History GuillainBarr√© syndrome within 6 week receipt prior influenza vaccine . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Fever time enrolment . Acute disease time enrolment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Ongoing aspirin therapy . Any condition , opinion Investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>